These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 5994042)

  • 21. [Methods and results of 15 years of official control of the efficacy of foot-and-mouth disease vaccines produced in France].
    Lucam F; Fédida M; Dannacher G
    Arch Exp Veterinarmed; 1970; 24():141-57. PubMed ID: 5515575
    [No Abstract]   [Full Text] [Related]  

  • 22. An early stage in the comparison of methods of modification of a field strain of foot-and-mouth disease, type A (Turkey 19-64).
    Quinones-Sowerby C; Knight EH; Taylor DI; McGrath T
    Bull Off Int Epizoot; 1966; 65(11):2071-89. PubMed ID: 4296535
    [No Abstract]   [Full Text] [Related]  

  • 23. [Use of guinea pigs in the effectiveness control of vaccines against Foot-and-mouth disease].
    Láznicka F; Hubík R; Hrib J
    Vet Med (Praha); 1971; 16(4):269-80. PubMed ID: 5006066
    [No Abstract]   [Full Text] [Related]  

  • 24. Chimeric foot-and-mouth disease viruses: evaluation of their efficacy as potential marker vaccines in cattle.
    Fowler VL; Paton DJ; Rieder E; Barnett PV
    Vaccine; 2008 Apr; 26(16):1982-9. PubMed ID: 18342409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The effect of temperature during passage on the properties of attenuated foot and mouth disease virus].
    Urvantsev NM; Siusiukin AA; Sergeev VA; Prokhorov VV
    Veterinariia; 1971 Jan; 1():37-9. PubMed ID: 4325013
    [No Abstract]   [Full Text] [Related]  

  • 26. Immune responses of recombinant adenovirus co-expressing VP1 of foot-and-mouth disease virus and porcine interferon alpha in mice and guinea pigs.
    Du Y; Dai J; Li Y; Li C; Qi J; Duan S; Jiang P
    Vet Immunol Immunopathol; 2008 Aug; 124(3-4):274-83. PubMed ID: 18511133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of immune responses to different foot-and-mouth disease genetically engineered vaccines in guinea pigs.
    Yao Q; Qian P; Huang Q; Cao Y; Chen H
    J Virol Methods; 2008 Jan; 147(1):143-50. PubMed ID: 17963851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [On the immunizing properties of GOAL-formol vaccine and GNKI dry virus vaccine against foot-and-mouth disease].
    Lazarev PS; Amelin IP; Zaslonov MS
    Veterinariia; 1966 Sep; 43(9):30-1. PubMed ID: 6011469
    [No Abstract]   [Full Text] [Related]  

  • 29. Observations on the use of BHK 21 Clone 13 cells for foot-and-mouth disease vaccine production.
    Capstick PB; Garland AJ
    Bull Off Int Epizoot; 1965 May; 64():215-23. PubMed ID: 5868390
    [No Abstract]   [Full Text] [Related]  

  • 30. [Efficacy of an emergency vaccine against foot and mouth disease in pigs].
    Eblé P
    Tijdschr Diergeneeskd; 2007 Aug; 132(16):617-9. PubMed ID: 17849910
    [No Abstract]   [Full Text] [Related]  

  • 31. High potency vaccines induce protection against heterologous challenge with foot-and-mouth disease virus.
    Brehm KE; Kumar N; Thulke HH; Haas B
    Vaccine; 2008 Mar; 26(13):1681-7. PubMed ID: 18313814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The effectiveness of vaccination to prevent foot and mouth disease in several species].
    Orsel K
    Tijdschr Diergeneeskd; 2008 Jan; 133(1):14-6. PubMed ID: 18260556
    [No Abstract]   [Full Text] [Related]  

  • 33. [Safety of foot-and-mouth disease vaccines in cell cultures].
    Tekerlekov P; Dilovski M; Gergov P; Nikolova E
    Vet Med Nauki; 1982; 19(1):21-5. PubMed ID: 6287707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of immune responses against foot-and-mouth disease virus induced by fusion proteins using the swine IgG heavy chain constant region or beta-galactosidase as a carrier of immunogenic epitopes.
    Li G; Chen W; Yan W; Zhao K; Liu M; Zhang J; Fei L; Xu Q; Sheng Z; Lu Y; Zheng Z
    Virology; 2004 Oct; 328(2):274-81. PubMed ID: 15464847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Transmissibility of infectious ribonucleic acid from neurotropic foot-and-mouth disease virus from murine brains to the brains of small laboratory animals].
    Hantschel H
    Arch Exp Veterinarmed; 1968; 22(3):491-7. PubMed ID: 4304281
    [No Abstract]   [Full Text] [Related]  

  • 36. Construction and immunogenicity of a recombinant fowlpox virus containing the capsid and 3C protease coding regions of foot-and-mouth disease virus.
    Zheng M; Jin N; Zhang H; Jin M; Lu H; Ma M; Li C; Yin G; Wang R; Liu Q
    J Virol Methods; 2006 Sep; 136(1-2):230-7. PubMed ID: 16780963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of immunologicals in the European union: current and emerging issues.
    Kriz NG;
    Biologicals; 2005 Dec; 33(4):247-52. PubMed ID: 16289997
    [No Abstract]   [Full Text] [Related]  

  • 38. Making a vaccinate-to-live policy a reality in foot-and-mouth disease.
    Mackay D; Parida S; Paton D; Anderson J
    Dev Biol (Basel); 2004; 119():261-6. PubMed ID: 15742637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Testing the activity of anti-foot-and-mouth disease aluminum hydroxide formol vaccine on guinea pigs].
    Kuleshova LA; Kozlovskiĭ GA; Sorvachev EV; Murashkin VI
    Veterinariia; 1969 May; 5():25-7. PubMed ID: 5381315
    [No Abstract]   [Full Text] [Related]  

  • 40. Foot-and-mouth disease vaccine potency testing in cattle using homologous and heterologous challenge strains: precision of the "Protection against Podal Generalisation" test.
    Goris N; Maradei E; D'Aloia R; Fondevila N; Mattion N; Perez A; Smitsaart E; Nauwynck HJ; La Torre J; Palma E; De Clercq K
    Vaccine; 2008 Jun; 26(27-28):3432-7. PubMed ID: 18499310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.